Shareholder Alert: Ademi LLP investigates whether ChemoCentryx, Inc. has obtained a Fair Price in its transaction with Amgen
MILWAUKEE, Aug. 4, 2022 /PRNewswire/ -- Ademi LLP is investigating ChemoCentryx (NASDAQ: CCXI) for possible breaches of fiduciary duty and other violations of law in its transaction with Amgen.
Click here to learn how to join the action: https://www.ademilaw.com/case/chemocentryx-inc-0 or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.
Ademi LLP alleges ChemoCentryx's financial outlook and prospects are excellent and yet ChemoCentryx holders will receive only $52 per share in cash, representing an enterprise value of approximately $3.7 billion. The transaction agreement unreasonably limits competing bids for ChemoCentryx by imposing a significant penalty if ChemoCentryx accepts a superior bid. ChemoCentryx insiders will receive substantial benefits as part of change of control arrangements.
We are investigating the conduct of ChemoCentryx's board of directors, and whether they are (i) fulfilling their fiduciary duties to all shareholders, and (ii) obtaining a fair and reasonable price for ChemoCentryx.
If you own ChemoCentryx common stock and wish to obtain additional information, please contact Guri Ademi either at [email protected] or toll-free: 866-264-3995, or https://www.ademilaw.com/case/chemocentryx-inc-0.
We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
Ademi LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001
SOURCE Ademi LLP
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article